Next Article in Journal
Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy
Next Article in Special Issue
Fingolimod Plays Role in Attenuation of Myocardial Injury Related to Experimental Model of Cardiac Arrest and Extracorporeal Life Support Resuscitation
Previous Article in Journal
Endogenous Retroviruses Activity as a Molecular Signature of Neurodevelopmental Disorders
Previous Article in Special Issue
Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment
Open AccessReview

Colon Cancer and Perturbations of the Sphingolipid Metabolism

Department of Chemistry and Toxicology, Veterinary Research Institute, Hudcova 296/70, 62100 Brno, Czech Republic
Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Poštovská 68/3, 60200 Brno, Czech Republic
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(23), 6051;
Received: 31 October 2019 / Revised: 25 November 2019 / Accepted: 28 November 2019 / Published: 30 November 2019
(This article belongs to the Special Issue Sphingolipids: Metabolic Functions and Disorders)
The development and progression of colorectal cancer (CRC), a major cause of cancer-related death in the western world, is accompanied with alterations of sphingolipid (SL) composition in colon tumors. A number of enzymes involved in the SL metabolism have been found to be deregulated in human colon tumors, in experimental rodent studies, and in human colon cancer cells in vitro. Therefore, the enzymatic pathways that modulate SL levels have received a significant attention, due to their possible contribution to CRC development, or as potential therapeutic targets. Many of these enzymes are associated with an increased sphingosine-1-phosphate/ceramide ratio, which is in turn linked with increased colon cancer cell survival, proliferation and cancer progression. Nevertheless, more attention should also be paid to the more complex SLs, including specific glycosphingolipids, such as lactosylceramides, which can be also deregulated during CRC development. In this review, we focus on the potential roles of individual SLs/SL metabolism enzymes in colon cancer, as well as on the pros and cons of employing the current in vitro models of colon cancer cells for lipidomic studies investigating the SL metabolism in CRC. View Full-Text
Keywords: colorectal cancer; colon cancer cells; sphingolipid; glycosphingolipid; colon cancer (CRC) sphingolipidomics; sphingosine-1-phosphate; lactosylceramide colorectal cancer; colon cancer cells; sphingolipid; glycosphingolipid; colon cancer (CRC) sphingolipidomics; sphingosine-1-phosphate; lactosylceramide
Show Figures

Figure 1

MDPI and ACS Style

Machala, M.; Procházková, J.; Hofmanová, J.; Králiková, L.; Slavík, J.; Tylichová, Z.; Ovesná, P.; Kozubík, A.; Vondráček, J. Colon Cancer and Perturbations of the Sphingolipid Metabolism. Int. J. Mol. Sci. 2019, 20, 6051.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop